Phase 2 trial of brentuximab vedotin plus AVD for non-bulky limited-stage Hodgkin lymphoma

Jeremy Abramson

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jeremy S. Abramson, MD, of the Massachusetts General Hospital Cancer Center, Boston, MA, discusses a multicenter Phase 2 study that is evaluating brentuximab vedotin, an antibody-drug conjugate, plus doxorubicin (adriamycin), vinblastine and dacarbazine (AVD) for the treatment of patients with non-bulky limited-stage classical Hodgkin lymphoma.

Share this video